SLS
SLS clinical trials: SELLAS Life Sciences Group, Inc.
Every trial on ClinicalTrials.gov where SELLAS Life Sciences Group, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 7
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
SLS on the catalyst calendar · SLS registry changes
- Primary completion Dec 30, 2026Sponsor estimatePhase 1/Phase 2NCT04588922Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly...Sellas Life Sciences Group · Hematologic MalignanciesRecruitingSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05593185Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDSSellas Life Sciences Group · Acute Myeloid LeukemiaAvailableSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2025Sponsor estimatePhase 3NCT04229979Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2Sellas Life Sciences Group · Acute Myeloid LeukemiaActive, not recruitingSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2016ActualPhase 2NCT01266083WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)Sellas Life Sciences Group · Acute Myeloid LeukemiaCompletedSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 5, 2022ActualPhase 1/Phase 2NCT03761914Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersSellas Life Sciences Group · Acute Myelogenous LeukemiaCompletedSLSLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2016ActualPhase 2NCT01265433Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapySellas Life Sciences Group · Malignant Pleural MesotheliomaCompletedSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 7, 2016ActualPhase 1/Phase 2NCT01827137WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell TransplantationSellas Life Sciences Group · Multiple MyelomaCompletedSLSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2021ActualPhase 2NCT02297698Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer PatientsCancer Insight, LLC · Breast CancerCompletedSLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2018ActualPhase 2NCT01570036Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVaxGeorge E. Peoples · Breast CancerCompletedSLSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner